Salvage with erlotinib plus bevacizumab: not in NSCLC
- PMID: 21621709
- DOI: 10.1016/S0140-6736(11)60740-X
Salvage with erlotinib plus bevacizumab: not in NSCLC
Comment on
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X. Lancet. 2011. PMID: 21621716 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
